-
1دورية أكاديمية
المؤلفون: Mastall, Maximilian, Roth, Patrick, Bink, Andrea, Fischer Maranta, Angela, Läubli, Heinz, Hottinger, Andreas Felix, Hundsberger, Thomas, Migliorini, Denis, Ochsenbein, Adrian, Seystahl, Katharina, Imbach, Lukas, Hortobagyi, Tibor, Held, Leonhard, Weller, Michael, Wirsching, Hans-Georg
المصدر: ISSN: 1471-2407 ; BMC cancer, vol. 24, no. 1 (2024) 82.
مصطلحات موضوعية: info:eu-repo/classification/ddc/616, Cancer neuroscience, Epilepsy, Gabapentin, Memantine, Sulfasalazine, Adult, Humans, Glioblastoma / drug therapy, Glioblastoma / genetics, Temozolomide / therapeutic use, Quality of Life, Drug Repositioning, Chemoradiotherapy, Brain Neoplasms / drug therapy, Brain Neoplasms / genetics, Steroids / therapeutic use, Glutamates, Randomized Controlled Trials as Topic, Multicenter Studies as Topic, Clinical Trials, Phase I as Topic
الوصف: Background: Glioblastoma is the most common and most aggressive malignant primary brain tumor in adults. Glioblastoma cells synthesize and secrete large quantities of the excitatory neurotransmitter glutamate, driving epilepsy, neuronal death, tumor growth and invasion. Moreover, neuronal networks interconnect with glioblastoma cell networks through glutamatergic neuroglial synapses, activation of which induces oncogenic calcium oscillations that are propagated via gap junctions between tumor cells. The primary objective of this study is to explore the efficacy of brain-penetrating anti-glutamatergic drugs to standard chemoradiotherapy in patients with glioblastoma. Methods/design: GLUGLIO is a 1:1 randomized phase Ib/II, parallel-group, open-label, multicenter trial of gabapentin, sulfasalazine, memantine and chemoradiotherapy (Arm A) versus chemoradiotherapy alone (Arm B) in patients with newly diagnosed glioblastoma. Planned accrual is 120 patients. The primary endpoint is progression-free survival at 6 months. Secondary endpoints include overall and seizure-free survival, quality of life of patients and caregivers, symptom burden and cognitive functioning. Glutamate levels will be assessed longitudinally by magnetic resonance spectroscopy. Other outcomes of interest include imaging response rate, neuronal hyperexcitability determined by longitudinal electroencephalography, Karnofsky performance status as a global measure of overall performance, anticonvulsant drug use and steroid use. Tumor tissue and blood will be collected for translational research. Subgroup survival analyses by baseline parameters include segregation by age, extent of resection, Karnofsky performance status, O 6 -methylguanine DNA methyltransferase (MGMT) promotor methylation status, steroid intake, presence or absence of seizures, tumor volume and glutamate levels determined by MR spectroscopy. The trial is currently recruiting in seven centers in Switzerland. Trial registration: NCT05664464 . Registered 23 December 2022.
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38225589; https://archive-ouverte.unige.ch/unige:174487Test; unige:174487
-
2دورية أكاديمية
المؤلفون: Kai Yu, Shobana Athimulam, Jasmine Saini, Ravinder Jeet Kaur, Qingping Xue, Travis J. McKenzie, Ravinder J. Singh, Stefan K. Grebe, Irina Bancos
مصطلحات موضوعية: Endocrinology, Steroids/therapeutic use, adrenocortical carcinoma (ACC), Adrenal incidentaloma, Diagnosis (computer-assisted)
الوصف: Serum steroid profiling in the diagnosis of adrenocortical carcinoma: a prospective cohort study
-
3دورية أكاديمية
المساهمون: Eun-Ki Min, Juhan Lee, Su Jin Jeong, Deok-Gie Kim, Seung Hyuk Yim, Mun Chae Choi, Dong Jin Joo, Myoung Soo Kim, Jae Geun Lee, Kim, Myoung Soo
مصطلحات موضوعية: Aged, Carcinoma, Hepatocellular, Case-Control Studies, Cytomegalovirus Infections* / complications, Humans, Liver Neoplasms, Liver Transplantation* / adverse effects, Lymphopenia, Pneumocystis carinii, Pneumonia, Pneumocystis* / drug therapy, Retrospective Studies, Risk Factors, Steroids / therapeutic use, Transplant Recipients, Liver transplantation, Pneumocystis jirovecii pneumonia, Risk factor
الوصف: Objectives: The risk factors for late-onset Pneumocystis jirovecii pneumonia (PCP) after liver transplantation (LT) have not been well studied. We aimed to analyze the clinical features preceding PCP in LT recipients that would guide individualized prophylaxis. Methods: Among 742 patients who underwent LT and routine PCP prophylaxis from January 2009 through December 2019 at Severance Hospital, 27 patients developed PCP. We conducted a retrospective case-control study matching each patient with four controls and analyzed the risk factors for late-onset PCP. Results: After 6 months, post-transplant PCP cases increased steadily with an overall incidence of 6.36 cases per 1000 patient-year. The PCP-related mortality was 37.0%. In the multivariate analyses, age at LT ≥65 years (odds ratio [OR], 13.305; 95% confidence interval [CI], 2.507-70.618; P = 0.002), cytomegalovirus infection (OR, 5.390; 95% CI, 1.602-18.132; P = 0.006), steroid pulse therapy (OR, 6.564; 95% CI, 1.984-21.719; P = 0.002), hepatocellular carcinoma recurrence (OR, 18.180; 95% CI, 3.420-96.636; P = 0.001), and lymphocytopenia (OR, 3.758; 95% CI, 1.176-12.013; P = 0.026) were independently associated with PCP. Conclusion: Late-onset PCP after routine prophylaxis after LT remains a lethal infection and is associated with age ≥65 years at LT, cytomegalovirus infection, steroid pulse therapy, hepatocellular carcinoma recurrence, and lymphocytopenia. Targeted prophylaxis considering these risk factors could improve the prevention of this potentially lethal complication. ; open
وصف الملف: application/pdf
العلاقة: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES; J01125; OAK-2023-01476; OAK-2023-01477; OAK-2023-01478; OAK-2023-01479; OAK-2023-01480; https://ir.ymlib.yonsei.ac.kr/handle/22282913/195335Test; T202302955; INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, Vol.131 : 166-172, 2023-06
الإتاحة: https://doi.org/10.1016/j.ijid.2023.04.387Test
https://ir.ymlib.yonsei.ac.kr/handle/22282913/195335Test -
4دورية أكاديمية
المؤلفون: Jaun, F., Tröster, L.M., Giezendanne, S., Bridevaux, P.O., Charbonnier, F., Clarenbach, C., Gianella, P., Jochmann, A., Kern, L., Miedinger, D., Pavlov, N., Rothe, T., Steurer-Stey, C., von Garnier, C., Leuppi, J.D.
المصدر: Respiration; international review of thoracic diseases, vol. 102, no. 10, pp. 863-878
مصطلحات موضوعية: Humans, Female, Adolescent, Young Adult, Adult, Middle Aged, Aged, 80 and over, Male, Anti-Asthmatic Agents/therapeutic use, Switzerland/epidemiology, Administration, Inhalation, Asthma/drug therapy, Asthma/epidemiology, Adrenal Cortex Hormones/therapeutic use, Steroids/therapeutic use, Biological Products/therapeutic use, Asthma control, Cohort, Predictors, Severe asthma
الوصف: Asthma is a chronic airway disease, affecting over 300 million people worldwide. 5-10% of patients suffer from severe asthma and account for 50% of asthma-related financial burden. Availability of real-life data about the clinical course of severe asthma is insufficient. The aims of this study were to characterize patients with severe asthma in Switzerland, enrolled in the Swiss Severe Asthma Registry (SSAR), and evaluate predictors for asthma control. A descriptive characterisation of 278 patients was performed, who were prospectively enrolled in the registry until January 2022. Socio-demographic variables, comorbidities, diagnostic values, asthma treatment, and healthcare utilisation were evaluated. Groups of controlled and uncontrolled asthma according to the asthma control test were compared. Forty-eight percent of patients were female and the mean age was 55.8 years (range 13-87). The mean body mass index (BMI) was 27.4 kg/m2 (±6). 10.8% of patients were current smokers. Allergic comorbidities occurred in 54.3% of patients, followed by chronic rhinosinusitis (46.4%) and nasal polyps (34.1%). According to the ACT score, 54.7% had well controlled, 16.2% partly controlled and 25.9% uncontrolled asthma. The most common inhalation therapy was combined inhaled corticosteroids/long-acting β2-agonists (78.8%). Biologics were administered to 81.7% of patients and 19.1% received oral steroids. The multivariable analysis indicated that treatment with biologics was positively associated with asthma control whereas higher BMI, oral steroids, exacerbations, and COPD were negative predictors for asthma control. Biologics are associated with improved control in severe asthma. Further studies are required to complete the picture of severe asthma in order to provide improved care for those patients.
وصف الملف: application/pdf
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37769646; info:eu-repo/semantics/altIdentifier/eissn/1423-0356; info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_23E18D3B506D0; https://serval.unil.ch/notice/serval:BIB_23E18D3B506DTest; urn:issn:0025-7931; https://serval.unil.ch/resource/serval:BIB_23E18D3B506D.P001/REF.pdfTest; http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_23E18D3B506D0Test
الإتاحة: https://doi.org/10.1159/000533474Test
https://serval.unil.ch/notice/serval:BIB_23E18D3B506DTest
https://serval.unil.ch/resource/serval:BIB_23E18D3B506D.P001/REF.pdfTest
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_23E18D3B506D0Test -
5دورية أكاديمية
المؤلفون: Jaun, Fabienne, Tröster, Lydia Marie, Giezendanne, Stéphanie, Bridevaux, Pierre-Olivier, Charbonnier, Florian, Clarenbach, Christian, Gianella, Pietro, Jochmann, Anja, Kern, Lukas, Miedinger, David, Pavlov, Nikolay, Rothe, Thomas, Steurer-Stey, Claudia, von Garnier, Christophe, Leuppi, Jorg D
المصدر: ISSN: 0025-7931 ; Respiration, vol. 102, no. 10 (2023) p. 863-878.
مصطلحات موضوعية: info:eu-repo/classification/ddc/616, Asthma control, Cohort, Predictors, Severe asthma, Administration, Inhalation, Adolescent, Adrenal Cortex Hormones / therapeutic use, Adult, Aged, 80 and over, Anti-Asthmatic Agents / therapeutic use, Asthma / drug therapy, Asthma / epidemiology, Biological Products / therapeutic use, Female, Humans, Male, Middle Aged, Steroids / therapeutic use, Switzerland / epidemiology, Young Adult
الوصف: Background: Asthma is a chronic airway disease, affecting over 300 million people worldwide. 5-10% of patients suffer from severe asthma and account for 50% of asthma-related financial burden. Availability of real-life data about the clinical course of severe asthma is insufficient. Objectives: The aims of this study were to characterize patients with severe asthma in Switzerland, enrolled in the Swiss Severe Asthma Registry (SSAR), and evaluate predictors for asthma control. Method: A descriptive characterisation of 278 patients was performed, who were prospectively enrolled in the registry until January 2022. Socio-demographic variables, comorbidities, diagnostic values, asthma treatment, and healthcare utilisation were evaluated. Groups of controlled and uncontrolled asthma according to the asthma control test were compared. Results: Forty-eight percent of patients were female and the mean age was 55.8 years (range 13-87). The mean body mass index (BMI) was 27.4 kg/m 2 (±6). 10.8% of patients were current smokers. Allergic comorbidities occurred in 54.3% of patients, followed by chronic rhinosinusitis (46.4%) and nasal polyps (34.1%). According to the ACT score, 54.7% had well controlled, 16.2% partly controlled and 25.9% uncontrolled asthma. The most common inhalation therapy was combined inhaled corticosteroids/long-acting β2-agonists (78.8%). Biologics were administered to 81.7% of patients and 19.1% received oral steroids. The multivariable analysis indicated that treatment with biologics was positively associated with asthma control whereas higher BMI, oral steroids, exacerbations, and COPD were negative predictors for asthma control. Conclusion: Biologics are associated with improved control in severe asthma. Further studies are required to complete the picture of severe asthma in order to provide improved care for those patients.
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37769646; https://archive-ouverte.unige.ch/unige:173030Test; unige:173030
-
6دورية أكاديمية
المؤلفون: Fenne, Inger Johanne, Askildsen Oftebro, Guro, Vestergaard, Christian, Frølunde, Anne Sofie, Bech, Rikke
المصدر: Fenne , I J , Askildsen Oftebro , G , Vestergaard , C , Frølunde , A S & Bech , R 2023 , ' Effect of early initiation of steroid-sparing drugs in patients with bullous pemphigoid ' , Frontiers in Immunology , vol. 14 , 1176284 . https://doi.org/10.3389/fimmu.2023.1176284Test
مصطلحات موضوعية: Glucocorticoids/therapeutic use, Humans, Pemphigoid, Bullous/chemically induced, Prednisolone/adverse effects, Recurrence, Retrospective Studies, Steroids/therapeutic use
الوصف: INTRODUCTION: Bullous pemphigoid (BP) can be treated using systemic and topical glucocorticoids and/or other immunomodulatory agents. However, the long-term use of systemic glucocorticoids causes severe adverse side effects. This study was aimed at investigating whether the early initiation of corticosteroid-sparing therapy (CST) in BP patients results in better outcomes than late or no CST. METHOD: We retrospectively identified all BP patients referred to the tertiary center, of the Department of Dermatology and Venerology, Aarhus University Hospital, Denmark, from 2015 to 2021. Patients' demographics, comorbidities, treatment, remission of BP, length of admission, relapse, and 1-year mortality were recorded. All patients who received CST were dichotomised into two groups: initiated with CST <28 or >28 days. The groups were compared using t-tests. Additionally, all patients who received CST were compared with those who received systemic glucocorticoids alone. Our cohort was compared with that of a previous study (2006-2013) performed in our department. In 2015, we revised our BP treatment guidelines to include the early initiation of CST. RESULTS: On comparing the group of patients initiated with CST <28 versus >28 days, we found no significant differences in the complications or mortality between the groups (p = 0.63 and p=0.79, respectively). The <28 days group had a lower rate of relapse (p < 0.05). On comparing data from this study with those from the previous study, conducted before we revised our treatment guideline, we found a reduced initial dose of prednisolone and reduced admission time in this study. No significant differences were found between patients treated with CST and those treated with systemic glucocorticoids alone. CONCLUSION: The rate of complications and 1-year mortality did not differ significantly between the two subgroups in this study. The relapse rate was lower in the CST <28 days group than in the CST >28 days group. The initial dose of prednisolone and ...
الإتاحة: https://doi.org/10.3389/fimmu.2023.1176284Test
https://pure.au.dk/portal/en/publications/dab78657-6f05-47fd-8afd-cae167181b3eTest -
7دورية أكاديمية
المؤلفون: Mastall, M., Roth, P., Bink, A., Fischer Maranta, A., Läubli, H., Hottinger, A.F., Hundsberger, T., Migliorini, D., Ochsenbein, A., Seystahl, K., Imbach, L., Hortobagyi, T., Held, L., Weller, M., Wirsching, H.G.
المصدر: BMC cancer, vol. 24, no. 1, pp. 82
مصطلحات موضوعية: Adult, Humans, Glioblastoma/drug therapy, Glioblastoma/genetics, Temozolomide/therapeutic use, Quality of Life, Drug Repositioning, Chemoradiotherapy, Brain Neoplasms/drug therapy, Brain Neoplasms/genetics, Steroids/therapeutic use, Glutamates, Randomized Controlled Trials as Topic, Multicenter Studies as Topic, Clinical Trials, Phase I as Topic, Cancer neuroscience, Epilepsy, Gabapentin, Memantine, Sulfasalazine
الوصف: Glioblastoma is the most common and most aggressive malignant primary brain tumor in adults. Glioblastoma cells synthesize and secrete large quantities of the excitatory neurotransmitter glutamate, driving epilepsy, neuronal death, tumor growth and invasion. Moreover, neuronal networks interconnect with glioblastoma cell networks through glutamatergic neuroglial synapses, activation of which induces oncogenic calcium oscillations that are propagated via gap junctions between tumor cells. The primary objective of this study is to explore the efficacy of brain-penetrating anti-glutamatergic drugs to standard chemoradiotherapy in patients with glioblastoma. GLUGLIO is a 1:1 randomized phase Ib/II, parallel-group, open-label, multicenter trial of gabapentin, sulfasalazine, memantine and chemoradiotherapy (Arm A) versus chemoradiotherapy alone (Arm B) in patients with newly diagnosed glioblastoma. Planned accrual is 120 patients. The primary endpoint is progression-free survival at 6 months. Secondary endpoints include overall and seizure-free survival, quality of life of patients and caregivers, symptom burden and cognitive functioning. Glutamate levels will be assessed longitudinally by magnetic resonance spectroscopy. Other outcomes of interest include imaging response rate, neuronal hyperexcitability determined by longitudinal electroencephalography, Karnofsky performance status as a global measure of overall performance, anticonvulsant drug use and steroid use. Tumor tissue and blood will be collected for translational research. Subgroup survival analyses by baseline parameters include segregation by age, extent of resection, Karnofsky performance status, O 6 -methylguanine DNA methyltransferase (MGMT) promotor methylation status, steroid intake, presence or absence of seizures, tumor volume and glutamate levels determined by MR spectroscopy. The trial is currently recruiting in seven centers in Switzerland. NCT05664464. Registered 23 December 2022.
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38225589; info:eu-repo/semantics/altIdentifier/eissn/1471-2407; https://serval.unil.ch/notice/serval:BIB_5EBA66D24C63Test; urn:issn:1471-2407
الإتاحة: https://doi.org/10.1186/s12885-023-11797-zTest
https://serval.unil.ch/notice/serval:BIB_5EBA66D24C63Test -
8دورية أكاديمية
المساهمون: Hee Jung Kim, Miribi Rho, Kyung Bong Yoon, Minju Jo, Dong Woo Lee, Shin Hyung Kim, Kim, Shin Hyung
مصطلحات موضوعية: Aged, Analgesics, Opioid, Constriction, Pathologic / pathology, Female, Humans, Lumbar Vertebrae / pathology, Magnetic Resonance Imaging / methods, Pain / pathology, Paraspinal Muscles* / diagnostic imaging, Steroids / therapeutic use, elderly patients, epidural steroid injection, myosteatosis, pain management, paraspinal muscles, sarcopenia
الوصف: Background: An assessment of paraspinal muscle degeneration based on magnetic resonance imaging has been used to investigate both sarcopenia and myosteatosis. The morphologic changes in cross-sectional area and fat infiltration of the paraspinal muscles can affect pain outcomes after epidural steroid injection. Methods: Patients ≥65 years of age who underwent fluoroscopy-guided lumbar epidural steroid injections were enrolled. Good analgesia was defined as ≥50% reduction in pain score at 4 weeks after injection. Cross-sectional area and grade of fat infiltration of the paraspinal muscles on magnetic resonance images at the level of L3-L4 disc were measured. Patient demographics, pain-related factors, clinical factors, and paraspinal muscle measurements were compared between good and poor analgesia groups. The factors associated with pain outcomes after injection were identified using multivariate analysis. Results: A total of 245 patients consisting of 149 and 96 patients in the good and poor analgesia groups, respectively, fully satisfied the study criteria for analysis. Patients of older age, opioid use, and high-grade foraminal stenosis were frequently observed in the poor analgesia group. The grade of fat infiltration of the paraspinal muscles was significantly higher in the poor analgesia group (Grade 2, 20.8% vs. 42.7%, p < 0.001), and this result was predominantly observed in female patients. However, there was no difference in the muscle cross-sectional area between the two groups (18.29 ± 3.16 vs. 18.59 ± 3.03 cm2 /m2 , p = 0.460). The percentage of patients with good analgesia decreased as the grade of fat infiltration increased (Grade 0 = 75.0%, Grade 1 = 65.8%, Grade 2 = 43.0%, p < 0.001). Multivariate logistic regression analysis revealed that preinjection opioid use [adjusted odds ratio (aOR) = 1.926, 95% confidence interval (CI) = 1.084-3.422, p = 0.025], moderate to severe foraminal stenosis (aOR = 2.859, 95% CI = 1.371-5.965, p = 0.005), and high-grade fat infiltration of the paraspinal ...
العلاقة: PAIN PRACTICE; J02461; OAK-2022-07863; OAK-2022-07864; OAK-2022-07865; OAK-2022-07866; https://ir.ymlib.yonsei.ac.kr/handle/22282913/192083Test; T202203605; PAIN PRACTICE, Vol.22(7) : 621-630, 2022-09
الإتاحة: https://doi.org/10.1111/papr.13141Test
https://ir.ymlib.yonsei.ac.kr/handle/22282913/192083Test -
9دورية أكاديمية
المساهمون: Mi Yeon Cho, Ahreum Song, Kee Yang Chung, Mi Ryung Roh, Roh, Mi Ryung
مصطلحات موضوعية: Adrenal Cortex Hormones, Humans, Injections, Intralesional, Keloid* / surgery, Sleep Apnea, Obstructive* / drug therapy, Steroids / therapeutic use, Triamcinolone Acetonide
الوصف: Background: Keloids are a chronic disease and cause pain, pruritus, and limitation of motion. Intralesional corticosteroid injection is the first-line treatment, but its effects can be limited, even with repeated injections. Objective: To investigate the efficacy and safety of a tunneling method of corticosteroid injection compared with conventional intralesional injection. Materials and methods: A retrospective review was conducted of keloid patients treated with intralesional corticosteroid injection by conventional and tunneling methods. Results: A total of 119 cases of keloid were included in the study. Among 78 patients treated with 20 mg/mL triamcinolone, the Investigators' Global Assessment effectiveness score and Observer Scar Assessment Scale (OSAS) score were significantly higher in the tunneling group than the conventional group at 1 month. At 6 months, the tunneling group showed significantly higher effectiveness in the OSAS score than the conventional group. In the tunneling group, the interval between treatments was significantly longer than in the conventional group. The occurrence of side effects was lower in the tunneling method group than in the conventional method group. Conclusion: This study reveals the benefits of the tunneling method over the conventional method for therapeutic effect and side effects in keloid treatment. ; restriction
العلاقة: DERMATOLOGIC SURGERY; J00707; OAK-2022-06352; OAK-2022-06353; https://ir.ymlib.yonsei.ac.kr/handle/22282913/191544Test; https://journals.lww.com/dermatologicsurgery/Fulltext/2022/06000/A_Novel_Method_of_Steroid_Delivery_to_Improve_the.7.aspxTest; T202204727; DERMATOLOGIC SURGERY, Vol.48(6) : 631-635, 2022-06
الإتاحة: https://doi.org/10.1097/DSS.0000000000003432Test
https://ir.ymlib.yonsei.ac.kr/handle/22282913/191544Test
https://journals.lww.com/dermatologicsurgery/Fulltext/2022/06000/A_Novel_Method_of_Steroid_Delivery_to_Improve_the.7.aspxTest -
10دورية أكاديمية
المساهمون: Ji Hye Kim, Jae Young Kim, Hyung Woo Kim, Seung Hyeok Han, Tae-Hyun Yoo, Shin-Wook Kang, Jung Tak Park, Kang, Shin Wook
مصطلحات موضوعية: Adrenal Insufficiency* / drug therapy, Adrenal Insufficiency* / epidemiology, Aged, Humans, Hydrocortisone / therapeutic use, Kidney, Male, Middle Aged, Retrospective Studies, Steroids / therapeutic use, adrenal insufficiency, end-stage kidney disease, glucocorticoid, steroid
الوصف: Objective: The prevalence of adrenal insufficiency (AI) is increasing with an increase in the elderly population. Steroid replacement therapy (SRT) is often required in patients with AI because of acute symptoms and complications. The long-term effects of SRT on kidney function have not been well elucidated. Methods: Overall, 788 patients diagnosed with AI between 2010 and 2015 at Yonsei University Health System were retrospectively evaluated. SRT was defined when an equivalent dose of ≥5 mg/d of hydrocortisone was initiated within 30 days of AI diagnosis and maintained for >30 days. Those not included in the SRT group were identified as the no-SRT group. The primary outcome was 40% reduction in the estimated glomerular filtration rate compared with baseline sustained for ≥30 days or end-stage kidney disease development. Results: The mean age of was 63.1 ± 15.4 years, and 43.0% were men. The SRT group comprised 387 patients. During a median follow-up duration of 4.1 years, the primary outcome occurred in 118 (15.0%) patients. The outcome incidence rate was higher in the SRT group (4.61/100 patient-years) than in the no-SRT group (2.76/100 patient-years). When the subdistribution hazard ratio for kidney outcome was assessed with death as a competing risk, the risk was 67% higher in the SRT group than in the no-SRT group (subdistribution hazard ratio, 1.67; 95% confidence interval, 1.16-2.45; P = .006). This association was maintained with inverse probability of treatment weighting and adjustment for confounding variables. Conclusion: Kidney function decline was more prominent in patients with AI who received SRT. Further prospective evaluations are needed to confirm these findings. ; restriction
العلاقة: ENDOCRINE PRACTICE; J03409; OAK-2022-05869; OAK-2022-05870; OAK-2022-05871; OAK-2022-05872; OAK-2022-05873; https://ir.ymlib.yonsei.ac.kr/handle/22282913/191346Test; https://www.sciencedirect.com/science/article/abs/pii/S1530891X21014270?via%3DihubTest; T202203259; ENDOCRINE PRACTICE, Vol.28(4) : 384-390, 2022-04
الإتاحة: https://doi.org/10.1016/j.eprac.2021.12.015Test
https://ir.ymlib.yonsei.ac.kr/handle/22282913/191346Test
https://www.sciencedirect.com/science/article/abs/pii/S1530891X21014270?via%3DihubTest
النص الكامل